Role of parametric resonance in virological failure during HIV treatment interruption therapy

Lancet

Volumn 367, Issue 9518, 2006, Pages 1285-1289

  Breban, Romulus ^a   Blower, Sally ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CALCULATION; DRUG INTERMITTENT THERAPY; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; LINEAR SYSTEM; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; OSCILLATION; PRIORITY JOURNAL; SIMULATION; SPECTRUM; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD; BIOLOGICAL MODEL; CD4 LYMPHOCYTE COUNT; MULTIDRUG RESISTANCE;

CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 33646205051     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68543-7     Document Type: Note

References (35)

1. Altfeld M., and Walker B. Less or more? STI in acute and chronic HIV-1 infection. Nat Med 7 (2001) 881-884
2. Rosenberg E., Altfeld M., Poon S., et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407 (2000) 523-526
3. Dybul M., Chun T.-W., Yoder C., et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA 98 (2001) 15161-15166
4. Dybul M., Nies-Kraske E., Dewar R., et al. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis 189 (2004) 1974-1982
5. Davey R., Bhat N., Yoder C., et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 96 (1999) 15109-15114
6. Papasavvas E., Kostman J., Mounzer K., et al. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Medicine 1 (2004) 218-228
7. Charlene L. Weekend HIV drug holiday an effective strategy. Medscape Today July 13, 2004. http://www.medscape.com/viewarticle/483438 (accessed Feb 8, 2006)
8. Ananworanich J., Nuesch R., Le Braz M., et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 17 (2003) F33-F37
9. Lori F., Maserati R., Foli A., Seminari E., Timpone J., and Lisziewicz J. Structured treatment interruptions to control HIV-1 infection. Lancet 355 (2000) 287-288
10. Fagard C., Oxenius A., Gunthard H., et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 163 (2003) 1220-1226
11. Dybul M., Nies-Kraske E., Daucher M., et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 188 (2003) 388-396
12. Ortiz G., Wellons M., Brancato J., et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci USA 98 (2001) 13288-13293
13. Garcia F., Plana M., Ortiz G., et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 15 (2001) F29-F40
14. Butikov E. Parametric Resonance. Comp Sci Eng 3 (1999) 76-83
15. Guckenheimer J., and Holmes P. Nonlinear oscillations, dynamical systems, and bifurcations of vector fields (1997), Springer-Verlag, Berlin
16. Berge P., Pomeau Y., and Vidal C. Order within chaos (1986), Herman, Paris
17. Agur Z. Resonance and anti-resonance in the design of chemotherapeutic protocols. J Theor Med 1 (1998) 237-245
18. Swierniak A., Polanski A., and Kimmel M. Optimal control problems arising in cell-cycle-specific cancer chemotherapy. Cell Prolif 29 (1996) 117-139
19. Agur Z. The effect of drug schedule on responsiveness to chemotherapy. Ann NY Acad Sci 504 (1986) 274-277
20. Agur Z. Randomness, synchrony and population persistence. J Theor Biol 112 (1985) 677-693
21. Agur Z. Clinical trials of Zidovudine in HIV infection. Lancet 334 (1989) 1400
22. Agur Z., Arnon R., Sandak B., and Schechter B. Zidovudine toxicity to murine bone marrow may be affected by the exact frequency of drug administration. Exp Hematol 19 (1991) 364-368
23. Agur Z., Tagliabue G., Schechter B., and Ubezio P. AZT effect on the bone marrow - a new perspective on the Concorde Trials. J Biol Syst 3 (1995) 241-251
24. Dushoff J., Plotkin J., Levin S., and Earn D. Dynamical resonance can account for seasonality of influenza epidemics. Proc Natl Acad Sci USA 101 (2004) 16915-16916
25. Breban R., and Blower S. Role of parametric resonance in virologic failure during HIV treatment interruption therapy. http://www.biomath.medsch.ucla.edu/faculty/sblower/pdf/supplG.pdf (accessed Feb 14, 2006)
26. Neumann A., Lam N., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998) 103-107
27. Nowak M., and Bangham C. Population dynamics of immune respones to persistent viruses. Science 272 (1996) 74-79
28. Nowak M., Bonhoeffer S., Hill A., Boehme R., Thomas H., and McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 93 (1996) 4398-4402
29. Nowak M., and Robert M. Virus dynamics: mathematical principles of immunology and virology (2000), Oxford University Press, Oxford
30. Perelson A. Modelling viral and immune system dynamics. Nat Rev Immunol 2 (2002) 28-36
31. Austin D., White N., and Anderson R. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J Theor Biol 194 (1998) 313-339
32. Howe L., Leroux C., Issel C., and Montelaro R. Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype. J Virol 76 (2002) 10588-10597
33. Perelson A., Neumann A., Markowitz M., Leonard J., and Ho D. HIV-1 Dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271 (1996) 1582-1586
34. Clark D., de Boer R., Wolthers K., and Miedema F. T cell dynamics in HIV-1 infection. Adv Immunol 73 (1999) 301-327
35. McLean A., and Michie C. In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci USA 92 (1995) 3707-3711